
Alnylam stock plunges after cutting 2026 sales forecast and facing legal probe.
Alnylam Pharmaceuticals saw its stock drop sharply after it lowered its 2026 sales guidance by about $200 million due to slower demand for its TTR products. Despite a strong biotech sector, Alnylam's shares fell by $81.14 per share, losing about 25% ...

